Your browser doesn't support javascript.
loading
Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP Database.
Doneddu, Pietro Emiliano; Cocito, Dario; Manganelli, Fiore; Fazio, Raffaella; Briani, Chiara; Filosto, Massimiliano; Benedetti, Luana; Mazzeo, Anna; Marfia, Girolama Alessandra; Cortese, Andrea; Fierro, Brigida; Jann, Stefano; Beghi, Ettore; Clerici, Angelo Maurizio; Carpo, Marinella; Schenone, Angelo; Luigetti, Marco; Lauria, Giuseppe; Antonini, Giovanni; Rosso, Tiziana; Siciliano, Gabriele; Cavaletti, Guido; Liberatore, Giuseppe; Santoro, Lucio; Peci, Erdita; Tronci, Stefano; Ruiz, Marta; Cotti Piccinelli, Stefano; Toscano, Antonio; Mataluni, Giorgia; Piccolo, Laura; Cosentino, Giuseppe; Sabatelli, Mario; Nobile-Orazio, Eduardo.
Afiliación
  • Doneddu PE; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Italy.
  • Cocito D; Department of Neuroscience, University of Turin, Turin, Italy.
  • Manganelli F; Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy.
  • Fazio R; Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.
  • Briani C; Neurology Unit, Department of Neuroscience, University of Padua, Padua, Italy.
  • Filosto M; Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy.
  • Benedetti L; Neurology Unit, Sant'Andrea Hospital, La Spezia, Italy.
  • Mazzeo A; Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy.
  • Marfia GA; Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.
  • Cortese A; IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy.
  • Fierro B; Department of Experimental BioMedicine and Clinical Neurosciences (BioNeC), University of Palermo, Palermo, Italy.
  • Jann S; Department of Neuroscience, Niguarda Ca' Granda Hospital, Milan, Italy.
  • Beghi E; Laboratorio di Malattie Neurologiche, IRCCS-Istituto Mario Negri, Milan, Italy.
  • Clerici AM; Neurology Unit, Circolo and Macchi Foundation Hospital, Insubria University, DBSV, Varese, Italy.
  • Carpo M; ASST Bergamo Ovest-Ospedale Treviglio, Treviglio, Italy.
  • Schenone A; Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa and IRCCS AOU San Martino-IST, Genoa, Italy.
  • Luigetti M; Unit of Neurology, IRCCS Foundation Policlinico A. Gemelli, Rome, Italy.
  • Lauria G; Unit of Neuroalgology, IRCCS Foundation 'Carlo Besta' Neurological Institute, Milan, Italy.
  • Antonini G; Department of Biomedical and Clinical Sciences 'Luigi Sacco', University of Milan, Milan, Italy.
  • Rosso T; Unit of Neuromuscular Diseases, Department of Neurology Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, 'Sapienza' University of Rome, Sant'Andrea Hospital, Rome, Italy.
  • Siciliano G; ULSS2 Marca Trevigiana, UOC Neurologia-Castelfranco Veneto, Treviso, Italy.
  • Cavaletti G; Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
  • Liberatore G; School of Medicine and Surgery and Experimental Neurology Unit, University of Milano-Bicocca, Monza, Italy.
  • Santoro L; Neuromuscular and Neuroimmunology Service, Humanitas Clinical and Research Institute, Rozzano, Italy.
  • Peci E; Department of Neuroscience, Reproductive Sciences and Odontostomatology, University of Naples 'Federico II', Naples, Italy.
  • Tronci S; Department of Neuroscience, University of Turin, Turin, Italy.
  • Ruiz M; Division of Neuroscience, Department of Neurology, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.
  • Cotti Piccinelli S; Neurology Unit, Department of Neuroscience, University of Padua, Padua, Italy.
  • Toscano A; Center for Neuromuscular Diseases and Neuropathies, Unit of Neurology, ASST 'Spedali Civili', University of Brescia, Brescia, Italy.
  • Mataluni G; Department of Clinical and Experimental Medicine, Unit of Neurology, University of Messina, Messina, Italy.
  • Piccolo L; Dysimmune Neuropathies Unit, Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.
  • Cosentino G; IRCCS Foundation C. Mondino National Neurological Institute, Pavia, Italy.
  • Sabatelli M; Department of Experimental BioMedicine and Clinical Neurosciences (BioNeC), University of Palermo, Palermo, Italy.
  • Nobile-Orazio E; Unit of Neurology, IRCCS Foundation Policlinico A. Gemelli, Rome, Italy.
J Neurol Neurosurg Psychiatry ; 90(2): 125-132, 2019 02.
Article en En | MEDLINE | ID: mdl-30297520
OBJECTIVES: A few variants of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) have been described, but their frequency and evolution to typical CIDP remain unclear. To determine the frequency and characteristics of the CIDP variants, their possible evolution to typical CIDP, and treatment response. METHODS: We applied a set of diagnostic criteria to 460 patients included in a database of Italian patients with CIDP. Clinical characteristics and treatment response were reviewed for each patient. The Kaplan-Meier curve was used to estimate the progression rate from atypical to typical CIDP. RESULTS: At the time of inclusion, 376 (82%) patients had a diagnosis of typical CIDP while 84 (18%) had atypical CIDP, including 34 (7%) with distal acquired demyelinating symmetric neuropathy (DADS), 17 (4%) with purely motor, 17 (4%) with Lewis-Sumner syndrome (LSS) and 16 (3.5%) with purely sensory CIDP. Based on retrospective review of the symptoms and signs present at onset and for at least 1 year, 180 (39%) patients had an initial diagnosis compatible with atypical CIDP that in 96 (53%) patients evolved to typical CIDP. Mean disease duration was longer in patients evolving to typical CIDP than in those not evolving (p=0.0016). Patients with DADS and LSS had a less frequent response to immunoglobulin than those with typical CIDP, while patients with purely motor and sensory CIDP had a similar treatment response. CONCLUSIONS: The proportion of patients with atypical CIDP varies during the disease course. DADS and LSS have a less frequent response to intravenous immunoglobulin compared with typical CIDP, raising the possibility of a different underlying pathogenetic mechanism.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2019 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Polirradiculoneuropatía Crónica Inflamatoria Desmielinizante Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Neurol Neurosurg Psychiatry Año: 2019 Tipo del documento: Article País de afiliación: Italia
...